10.1016/j.bbapap.2014.11.008 150 SkopelitouK.MuletaA
Peripheral effects Via the AMY2 and AMY3 receptors Cagrilintide acts peripherally: Slowing of gastric emptying , stronger than with GLP-1 Suppression of postprandial glucagon , helps control postprandial glycemic spikes Modulation of bone remodeling (via AMY3), a neutral effect, but clinically monitored Synergy with GLP-1 (the mechanistic basis of CagriSema) The main innovation is the complementarity with the GLP-1 pathway : GLP-1 suppresses appetite via the arcuate nucleus of the hypothalamus (POMC neurons, AgRP/NPY inhibition) Amylin suppresses appetite via the area postrema (CGRP-like neurons) Two independent centers, two independent mechanisms
New England Journal of Medicine, 389(6), 514-526
The primary concern with hepatic impairment is a potential change in exposure to a drug that is extensively cleared by hepatic metabolism or biliary excretion via the liver, that could impact on the pharmacodynamic action or lead to adverse effects [19]
Rotate Injection Sites (If Using Sub-Q/IM): To minimize discomfort or tissue irritation, switch between different sites (e.g., thighs, abdomen, upper arms)
